Product menu

SHINGRIX: Private coverage & public funding information

Ontario publicly funded shingles (herpes zoster) program1

Overview: SHINGRIX is covered on the Ontario publicly funded shingles immunization program for Ontario seniors aged 65 to 70 years. Please note: As a result of the COVID-19 pandemic and response activities, individuals born in 1949 to 1953 who missed the opportunity to receive the publicly funded shingles vaccine are eligible to receive SHINGRIX and complete the 2-dose series by December 31, 2024.

For complete eligibility criteria, click the button below.

Access: Eligible individuals are able to receive SHINGRIX through their primary healthcare provider.

Learn more

Veterans Affairs Canada (VAC)2

Overview: SHINGRIX is covered on the Veterans Affairs Canada Federal Plan for all members 50 years of age and older.

Access: Eligible members require a prescription from their health professional authorized to prescribe pharmaceuticals.

Learn more

First Nations Health Authority (FNHA)3

Overview: SHINGRIX is covered by the First Nations Health Authority for First Nation Elders 60 years of age or older. Requests for vaccine coverage for those under 60 years of age will be considered if submitted with supporting medical documentation from a primary care provider.

Access: The SHINGRIX vaccine can be prescribed by a physician or nurse practitioner or obtained directly from the pharmacist.

Learn more

Non-Insured Health Benefits (NIHB) program4

Overview: SHINGRIX is covered on the Non-Insured Health Benefits program for clients aged ≥60 years (no prior approvals required). Additionally, NIHB will consider coverage for immunocompromised clients on an exceptional basis (prior approval required).

Access: Eligible individuals are able to receive SHINGRIX through their pharmacist (where applicable) or  primary healthcare provider.

Learn more

Private insurance

The cost of SHINGRIX may be covered by your patient’s private insurance. They can contact their insurance provider and give the DIN (drug identification number) below to find out.

SHINGRIX DIN: 02468425.

Prince Edward Island publicly funded shingles (herpes zoster) program5

Overview: SHINGRIX is covered by the provincial government for Prince Edward Island seniors aged ≥60 years.

Access: Eligible individuals are able to receive SHINGRIX through their pharmacist.

Learn more

Yukon publicly funded shingles (herpes zoster) program6

Overview: SHINGRIX is covered by the publicly funded shingles vaccine program for Yukoners aged 65 to 79 years.

Access: Eligible individuals are able to receive SHINGRIX at their Community Health Centre by appointments and through a pharmacist.

Learn more

Quebec publicly funded shingles (herpes zoster) vaccination program7

Overview: SHINGRIX is covered under the shingles vaccination program for people aged 75 years and older and people aged 18 years and older who are immunocompromised.

Access: Eligible individuals are able to receive SHINGRIX by booking an appointment with a vaccination centre or a pharmacy through Clic Santé.

Learn more

Alberta publicly funded shingles program8

Overview: SHINGRIX is covered under the shingles vaccination program for solid organ transplant recipients (pre and post solid organ transplant) and autologous hematopoietic stem cell transplant (HSCT) recipients 18 years of age and older (6 months post HCT).

Access: Eligible individuals are able to receive SHINGRIX by contacting their local public health or community health centre.

Learn more

Pain icon

Could immunocompromised patients aged ≥18 years be at risk of shingles?

Learn about different immunocompromised risk factors for shingles.9

Learn more
Virus icon

Did you know age is the dominant driver of shingles?

Learn about age-related decline in immunity.9

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.10

Learn more

References:

  1. Ontario Ministry of Health. Guidance for routine & catch-up immunization services. August 2022. Available at: https://health.gov.on.ca/en/pro/programs/immunization/docs/Guidance_for_Routine_CatchUp_Immunization_Services.pdf. Accessed November 30, 2022.
  2. Veterans Affairs Canada. Details: Drug 02468425: SHINGRIX suspension 50 mcg/0.5 mL. Available at: https://www.veterans.gc.ca/eng/financial-support/medical-costs/treatment-benefits/poc10/search/form_detail/02468425. Accessed November 30, 2022.
  3. First Nations Health Authority. Recent Changes to Coverage of Shingrix® Vaccine. September 01, 2023. Available at: https://www.fnha.ca/benefits/health-benefits-news/recent-changes-to-coverage-of-shingrix-vaccine-and-freestyle-libre-2-glucose-monitor. Accessed October 5, 2023.
  4. Indigenous Services Canada. Non-Insured Health Benefits program updates June 2023. Available at: https://www.sac-isc.gc.ca/eng/1578079214611/1578079236012#s23-06-a2. Accessed July 7, 2023
  5. Prince Edward Island Canada. Free shingles vaccine for Island seniors in January 2022. Available at: https://www.princeedwardisland.ca/en/news/free-shingles-vaccine-program-now-available-to-islanders-aged-60-and-over. Accessed July 7, 2023.
  6. Government of Yukon. Health 2023 Session Briefing. Available at: https://open.yukon.ca/sites/default/files/HSS-2023-Spring-SessionBrief.pdf. Accessed July 21, 2023.
  7. Quebec. Shingles vaccination program. Available at: https://www.quebec.ca/en/health/advice-and-prevention/vaccination/shingles-vaccination-program. Accessed May 1, 2024.
  8. Alberta Health Services. Herpes zoster non-live recombinant vaccine biological page. Available at: https://www.albertahealthservices.ca/assets/info/hp/cdc/if-hp-cdc-herpes-zost-vac-bio-pg-07-215.pdf. Accessed November 28, 2023.
  9. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
  10. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24